Literature DB >> 29063849

Prognostic Factors and Patterns of Locoregional Failure After Surgical Resection in Patients With Cholangiocarcinoma Without Adjuvant Radiation Therapy: Optimal Field Design for Adjuvant Radiation Therapy.

Zahra Ghiassi-Nejad1, Paola Tarchi2, Erin Moshier3, Meng Ru3, Parissa Tabrizian4, Myron Schwartz4, Michael Buckstein5.   

Abstract

PURPOSE: To identify prognostic factors and patterns of local failure in patients with cholangiocarcinoma (CCA), after surgical resection in the absence of adjuvant radiation, for optimal definition of target volumes encompassing the majority of local recurrences. METHODS AND MATERIALS: A chart review was performed in patients who underwent resection for primary CCA (intrahepatic, hilar, and distal) between 1999 and 2014. Local failure was defined as recurrence in a theoretical reasonable postoperative radiation volume. This includes the cut surface of liver, biliary anastomosis, hilum, portal nodes, celiac nodes, peri-pancreatic nodes, gastro-hepatic nodes, and retroperitoneal nodes. Patients who received adjuvant radiation were excluded.
RESULTS: A total of 189 patients underwent surgical resection for CCA, of whom 145 patients had sufficient follow-up. Median follow-up was 41.6 months (95% confidence interval 35.4-48.7 months). Of the 145 cases, 102 were intrahepatic and 43 were hilar/distal CCA. Adjuvant chemotherapy was given in 38 cases (26%), of which 20 (54%) were gemcitabine-based. Eighty-six patients (59%) had a documented recurrence, of whom 44 (51%) had a locoregional component. Among patients who had a recurrence, 23 (27%) had a recurrence at the biliary anastomosis and/or cut liver surface. Twenty-eight patients (32.6%) had a recurrence in the regional lymph nodes, most prevalent in the portal (16.3%) and retroperitoneal (17.4%) lymph nodes. Univariable analysis identified tumor size, any vascular invasion, presence of satellites, stage/nodal status, and receipt of chemotherapy as significant prognostic factors of overall recurrence among intrahepatic patients. Presence of satellites, and stage 3/Nx status remained statistically significant in multivariable modeling.
CONCLUSIONS: The areas at highest risk for locoregional recurrence after surgical resection for primary CCA are the biliary anastomosis/cut liver surface, portal lymph nodes, and retroperitoneal lymph nodes. Although these results need to be validated, adjuvant radiation should possibly cover these areas to maximize locoregional control.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29063849     DOI: 10.1016/j.ijrobp.2017.06.2467

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis.

Authors:  Seo Hee Choi; Chai Hong Rim; In-Soo Shin; Won Sup Yoon; Woong Sub Koom; Jinsil Seong
Journal:  Liver Cancer       Date:  2021-08-26       Impact factor: 11.740

2.  Hypericin Exerts Detrimental Effect on Huh-7 As a Delegacy of Hepatocellular Carcinoma: A P53 Dependent Pathway.

Authors:  Maedeh Olya; Hamid Zaferani Arani; Amirhossein Shekarriz; Amirhossein Zabolian; Hadi Zare Marzouni; Hoda Aryan; Mohammad Hoseinian; Mohammad Amin Javidi; Hesam Adin Atashi
Journal:  Galen Med J       Date:  2020-12-28

3.  Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation.

Authors:  Edward Christopher Dee; Morgan E Freret; Nora Horick; Ann C Raldow; Lipika Goyal; Andrew X Zhu; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jill N Allen; Cristina R Ferrone; Carlos Fernandez-Del Castillo; Kenneth K Tanabe; Lorraine C Drapek; Theodore S Hong; Motaz Qadan; Jennifer Y Wo
Journal:  Ann Surg Oncol       Date:  2020-08-01       Impact factor: 5.344

4.  Mapping of local recurrence after pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.

Authors:  Wonguen Jung; Kyubo Kim; Seog Ki Min; Eun Mi Nam; Jeong Kyong Lee
Journal:  Br J Radiol       Date:  2019-06-14       Impact factor: 3.039

5.  Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.

Authors:  Kai-Qian Zhou; Wei-Feng Liu; Liu-Xiao Yang; Yun-Fan Sun; Jie Hu; Fei-Yu Chen; Cheng Zhou; Xiang-Yu Zhang; Yuan-Fei Peng; Lei Yu; Jian Zhou; Jia Fan; Zheng Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

6.  Patterns of failure after resection of extrahepatic bile duct cancer: implications for adjuvant radiotherapy indication and treatment volumes.

Authors:  Hoon Sik Choi; Ki Mun Kang; Bae Kwon Jeong; Hojin Jeong; Yun Hee Lee; In Bong Ha; Tae Gyu Kim; Jin Ho Song
Journal:  Radiat Oncol       Date:  2018-05-08       Impact factor: 3.481

7.  Pattern of the First Recurrence Has No Impact on Long-Term Survival after Curative Intent Surgery for Perihilar Cholangiocarcinomas.

Authors:  Madalina Maria Blaga; Vladislav Brasoveanu; Cezar Stroescu; Mihnea Ionescu; Irinel Popescu; Traian Dumitrascu
Journal:  Gastroenterol Res Pract       Date:  2018-08-09       Impact factor: 2.260

8.  High expression of Oct4 and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection.

Authors:  Mei-Xia Zhang; Wei Gan; Chu-Yu Jing; Su-Su Zheng; Yong Yi; Juan Zhang; Xin Xu; Jia-Jia Lin; Bo-Heng Zhang; Shuang-Jian Qiu
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

9.  Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation.

Authors:  Margaret M Kozak; Diego A S Toesca; Rie von Eyben; Erqi L Pollom; Daniel T Chang
Journal:  Adv Radiat Oncol       Date:  2019-08-21

Review 10.  The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery.

Authors:  Lijuan Ding; Lihua Dong; Gaoyuan Wang; Qiang Wang; Xia Fan
Journal:  Cancer Manag Res       Date:  2019-12-30       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.